6976.TWO Acepodia, Inc.
- Market cap
- TWD 6.97B
- P/E
- -
- P/B
- 1.44x
- ROE
- -16.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6976.TWO undervalued?
Graham numberThe Graham number of Acepodia, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Acepodia, Inc. fundamental analysis
No fundamental analysis for Acepodia, Inc. yet.
Acepodia, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Acepodia, Inc.
Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; The company is based in Grand Cayman, the Cayman Islands.
Full company profileAcepodia, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Acepodia, Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 0.00 | 0.00 | 16.6M | 427K | 185K | - |
| Gross Profit | - | - | - | 16.6M | 278K | 121K | - |
| Operating Income | -150M | -477M | -1.41B | -812M | -758M | -969M | -982M |
| EBITDA | -451M | -866M | -1.39B | -765M | -386M | -642M | -698M |
| Net Income | -455M | -879M | -1.41B | -817M | -497M | -754M | -828M |
| EPS | -40 | -78 | -31 | -1.44 | -0.87 | -1.30 | -1.42 |
| Balance Sheet | |||||||
| Total Assets | 253M | 3.90B | 3.87B | 6.82B | 6.82B | 5.83B | 5.43B |
| Total Liabilities | 963M | 5.36B | 6.88B | 384M | 479M | 415M | 364M |
| Shareholders' Equity | -710M | -1.46B | -3.01B | 6.43B | 6.34B | 5.42B | 5.07B |
| Cash & Short-term Investments | 226M | 3.76B | 3.73B | 6.29B | 5.87B | 3.80B | 3.44B |
| Total Debt | 6.95M | 53.8M | 52.4M | 274M | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -103M | -358M | -373M | -283M | -369M | -707M | -738M |
| Capital Expenditure | 3.62M | 28.7M | 7.71M | 179M | 128M | 72.9M | 25.1M |
| Free Cash Flow | -107M | -387M | -380M | -462M | -497M | -780M | -763M |
| Ratios | |||||||
| ROE | - | - | - | -12.7% | -7.8% | -13.9% | -16.3% |
| ROA | -179.7% | -22.5% | -36.5% | -12.0% | -7.3% | -12.9% | -15.2% |
| Net Profit Margin | - | - | - | -4,925.7% | -116,334.4% | -407,784.3% | - |
| Debt to Equity | - | - | - | 0.04x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Acepodia, Inc. dividends
Acepodia, Inc. has not paid dividends in the last 6 fiscal years.
Who owns Acepodia, Inc.
Ownership data of Acepodia, Inc. is not available yet.
Acepodia, Inc. company profile
- Company name
- Acepodia, Inc.
- Ticker
- 6976.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Ugland House, Grand Cayman, Cayman Islands, KY1-1104
- Phone
- 345 02 2697 6100
- Website
- acepodia.com
About Acepodia, Inc.
Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; The company is based in Grand Cayman, the Cayman Islands.
Acepodia, Inc. management
9- Dr. Shih-Chia Hsiao Ph.D.Co-Founder, CEO, President & Chairman · born 1982
- Dr. Yuhmin Yang Ph.D.Co-Founder & Advisor · born 1948
- Ms. Grace ChouSenior Director of Finance
- Mr. YanDa LaiExecutive Director of Operations
- Ms. Yajun Wang Ph.D.Chief Technical Officer
- Ms. Jessica Lee M.B.A., M.S.Head of Business Development
- Dr. Arthur Foo Ph.D.Head of Clinical operation
- Dr. Erick HuangHead of Clinical Development
- Stephanie HsiaoSecretary